The global market for antibody-drug conjugates (ADCs) is witnessing significant momentum, propelled by advancements in medical research and the rising demand for targeted cancer therapies. ADCs represent a sophisticated class of therapeutics that combine the targeting capabilities of monoclonal antibodies with the cell-killing potency of cytotoxic drugs, offering a promising approach in the...